Free tool
Cell therapy stocks
We cover 2 companies grouped under the Cell therapy theme. The median market value in the group is $1.37B. Across the group, the median move over the past trading day is +1.75%. Price change over the past year runs from −51.3% to −4.8% across the middle 80 percent of the group, with a median of −28.0%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
2 of 86 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return | Next report |
|---|---|---|---|---|---|---|
| MSB.AX | Mesoblast Limited | 2.45 AUD | +19.85% | −11.73% | +1.03% | Aug 27, 2026 |
| 4592.T | SanBio Company Limited | 997.00 JPY | +10.78% | −39.10% | −57.08% | Sep 14, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.